Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8601947 | 0.82 | CD44 (0.41) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL9399667 | 0.78 | POLB (0.46) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL14241045 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL27812431 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL28126708 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL33589 | 0.73 | ALDH1A1 (0.65) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL139002 | 0.73 | ALDH1A1 (0.65) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL9793558 | 0.73 | — | — | |
| SCHEMBL91496 | 0.73 | RAPGEF4 (0.32) | — | |
| SCHEMBL8826929 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106079-B2 | Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7816552-B2 | Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100234612-A1 | Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1798216-A1 | INTERMEDIATE OF 6-SUBSTITUTED-1-METHYL-1-H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR PRODUCING SAME | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0614930-B1 | Modified gelatin types and hydrophilic elements containing them | AGFA GEVAERT NV (BE) | 1998-02-04 | — | — | EP | disclosed |
| US-5439791-A | Having amino, sulfinic acid or thiol end groups; enhanced reactivity with vinylsulfonyl hardeners | AGFA-GEVAERT, N.V. (BE) | 1995-08-08 | — | — | US | disclosed |
| EP-0614930-A1 | Modified gelatin types and hydrophilic elements containing them | AGFA-GEVAERT N.V. (BE) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ALDH1A1 28/4885TDP1 4444/4885CYP3A4 812/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ALDH1A1 28/4885TDP1 4444/4885CYP3A4 812/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | ALDH1A1 2128/4885TDP1 4798/4885CYP3A4 4276/4885 |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | AZI2, CYC1, CCNI | ALDH1A1 928/4885TDP1 2994/4885CYP3A4 250/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | ALDH1A1 2128/4885TDP1 4798/4885CYP3A4 4276/4885 |
| US-20100234612-A1 | Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same | CYC1, CYP2B6, COX6B1 | ALDH1A1 668/4885TDP1 3676/4885CYP3A4 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.